5 Questions: Progress in peanut-allergy immunotherapy

Stanford School of Medicine News Dec 02, 2018

Any parent of a child with a severe peanut allergy knows the peril of a PB&J. For those with the condition, just sitting next to someone eating peanut butter can trigger a life-threatening reaction.

Now, scientists have established the validity of what could become the first oral anti-peanut-allergy drug. Stanford was one of 66 sites to participate in a phase 3 clinical trial of the therapy. The results were published November 22 in The New England Journal of Medicine. Sharon Chinthrajah,...

Go to Original

General Medicine Allergy and Immunology

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.